Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 15 August 2006, Vol. 108, No. 4, pp. 1267-1279.
Prepublished online as a Blood First Edition Paper on April 18, 2006; DOI 10.1182/blood-2005-10-007252.


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Appendix
Right arrow All Versions of this Article:
blood-2005-10-007252v1
108/4/1267    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Caprioli, J.
Right arrow Articles by Remuzzi, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Caprioli, J.
Right arrow Articles by Remuzzi, G.
Related Collections
Right arrow Hemostasis, Thrombosis, and Vascular Biology
Right arrow Clinical Trials and Observations
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY

Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome

Jessica Caprioli, Marina Noris, Simona Brioschi, Gaia Pianetti, Federica Castelletti, Paola Bettinaglio, Caterina Mele, Elena Bresin, Linda Cassis, Sara Gamba, Francesca Porrati, Sara Bucchioni, Giuseppe Monteferrante, Celia J. Fang, M. K. Liszewski, David Kavanagh, John P. Atkinson, Giuseppe Remuzzi, for the International Registry of Recurrent and Familial HUS/TTP

From the Mario Negri Institute for Pharmacologic Research, Clinical Research Center for Rare Diseases, Aldo e Cele Daccò, Villa Camozzi, Ranica, Bergamo, Italy; Department of Nephrology and Dialysis, Azienda Ospedaliera, Ospedali Riuniti di Bergamo, Italy; Division of Rheumatology, Washington University School of Medicine, St Louis, MO; and Institute of Human Genetics, University of Newcastle upon Tyne, United Kingdom.

Hemolytic uremic syndrome (HUS) is a thrombotic microangiopathy with manifestations of hemolytic anemia, thrombocytopenia, and renal impairment. Genetic studies have shown that mutations in complement regulatory proteins predispose to non–Shiga toxin–associated HUS (non-Stx–HUS). We undertook genetic analysis on membrane cofactor protein (MCP), complement factor H (CFH), and factor I (IF) in 156 patients with non-Stx–HUS. Fourteen, 11, and 5 new mutational events were found in MCP, CFH, and IF, respectively. Mutation frequencies were 12.8%, 30.1%, and 4.5% for MCP, CFH, and IF, respectively. MCP mutations resulted in either reduced protein expression or impaired C3b binding capability. MCP-mutated patients had a better prognosis than CFH-mutated and nonmutated patients. In MCP-mutated patients, plasma treatment did not impact the outcome significantly: remission was achieved in around 90% of both plasma-treated and plasma-untreated acute episodes. Kidney transplantation outcome was favorable in patients with MCP mutations, whereas the outcome was poor in patients with CFH and IF mutations due to disease recurrence. This study documents that the presentation, the response to therapy, and the outcome of the disease are influenced by the genotype. Hopefully this will translate into improved management and therapy of patients and will provide the way to design tailored treatments.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Nephrol Dial TransplantHome page
P. Hirt-Minkowski, S. Schaub, M. Mayr, J. A. Schifferli, M. Dickenmann, V. Fremeaux-Bacchi, and J. Steiger
Haemolytic uraemic syndrome caused by factor H mutation: is single kidney transplantation under intensive plasmatherapy an option?
Nephrol. Dial. Transplant., November 1, 2009; 24(11): 3548 - 3551.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
M. Noris and G. Remuzzi
Atypical Hemolytic-Uremic Syndrome
N. Engl. J. Med., October 22, 2009; 361(17): 1676 - 1687.
[Full Text] [PDF]


Home page
BloodHome page
E. M. Conway
Super factor B-gets atypical HUS
Blood, September 24, 2009; 114(13): 2572 - 2574.
[Full Text] [PDF]


Home page
BloodHome page
L. T. Roumenina, M. Jablonski, C. Hue, J. Blouin, J. D. Dimitrov, M.-A. Dragon-Durey, M. Cayla, W. H. Fridman, M.-A. Macher, D. Ribes, et al.
Hyperfunctional C3 convertase leads to complement deposition on endothelial cells and contributes to atypical hemolytic uremic syndrome
Blood, September 24, 2009; 114(13): 2837 - 2845.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
T. Kwon, A. Belot, B. Ranchin, V. Baudouin, V. Fremeaux-Bacchi, M.-A. Dragon-Durey, P. Cochat, and C. Loirat
Varicella as a trigger of atypical haemolytic uraemic syndrome associated with complement dysfunction: two cases
Nephrol. Dial. Transplant., September 1, 2009; 24(9): 2752 - 2754.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
S. Strobel, P. F. Hoyer, C. J. Mache, E. Sulyok, W.-s. Liu, H. Richter, M. Oppermann, P. F. Zipfel, and M. Jozsi
Functional analyses indicate a pathogenic role of factor H autoantibodies in atypical haemolytic uraemic syndrome
Nephrol. Dial. Transplant., August 7, 2009; (2009) gfp388v1.
[Abstract] [Full Text] [PDF]


Home page
CJASNHome page
C. J. Mache, B. Acham-Roschitz, V. Fremeaux-Bacchi, M. Kirschfink, P. F. Zipfel, S. Roedl, U. Vester, and E. Ring
Complement Inhibitor Eculizumab in Atypical Hemolytic Uremic Syndrome
Clin. J. Am. Soc. Nephrol., August 1, 2009; 4(8): 1312 - 1316.
[Abstract] [Full Text] [PDF]


Home page
CJASNHome page
K. Lhotta, A. R. Janecke, J. Scheiring, B. Petzlberger, T. Giner, V. Fally, R. Wurzner, L. B. Zimmerhackl, G. Mayer, and V. Fremeaux-Bacchi
A Large Family with a Gain-of-Function Mutation of Complement C3 Predisposing to Atypical Hemolytic Uremic Syndrome, Microhematuria, Hypertension and Chronic Renal Failure
Clin. J. Am. Soc. Nephrol., August 1, 2009; 4(8): 1356 - 1362.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
M. Delvaeye, M. Noris, A. De Vriese, C. T. Esmon, N. L. Esmon, G. Ferrell, J. Del-Favero, S. Plaisance, B. Claes, D. Lambrechts, et al.
Thrombomodulin Mutations in Atypical Hemolytic-Uremic Syndrome
N. Engl. J. Med., July 23, 2009; 361(4): 345 - 357.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
M. J.G. Somers, A. Sharma, P. E. Grant, A. R. Guimaraes, and E. E. Schneeberger
Case 23-2009 -- A 13-Year-Old Boy with Headache, Nausea, Seizures, and Hypertension
N. Engl. J. Med., July 23, 2009; 361(4): 389 - 400.
[Full Text] [PDF]


Home page
J. Immunol.Home page
V. P. Ferreira, A. P. Herbert, C. Cortes, K. A. McKee, B. S. Blaum, S. T. Esswein, D. Uhrin, P. N. Barlow, M. K. Pangburn, and D. Kavanagh
The Binding of Factor H to a Complex of Physiological Polyanions and C3b on Cells Is Impaired in Atypical Hemolytic Uremic Syndrome
J. Immunol., June 1, 2009; 182(11): 7009 - 7018.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
J. M. Saland, P. Ruggenenti, G. Remuzzi, and and the Consensus Study Group
Liver-Kidney Transplantation to Cure Atypical Hemolytic Uremic Syndrome
J. Am. Soc. Nephrol., May 1, 2009; 20(5): 940 - 949.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
A. M. Risitano, R. Notaro, L. Marando, B. Serio, D. Ranaldi, E. Seneca, P. Ricci, F. Alfinito, A. Camera, G. Gianfaldoni, et al.
Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab
Blood, April 23, 2009; 113(17): 4094 - 4100.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
J. Nurnberger, T. Philipp, O. Witzke, A. O. Saez, U. Vester, H. A. Baba, A. Kribben, L. B. Zimmerhackl, A. R. Janecke, M. Nagel, et al.
Eculizumab for Atypical Hemolytic-Uremic Syndrome
N. Engl. J. Med., January 29, 2009; 360(5): 542 - 544.
[Full Text] [PDF]


Home page
NEJMHome page
R. A. Gruppo and R. P. Rother
Eculizumab for Congenital Atypical Hemolytic-Uremic Syndrome
N. Engl. J. Med., January 29, 2009; 360(5): 544 - 546.
[Full Text] [PDF]


Home page
BloodHome page
F. Fakhouri, M. Jablonski, J. Lepercq, J. Blouin, A. Benachi, M. Hourmant, Y. Pirson, A. Durrbach, J.-P. Grunfeld, B. Knebelmann, et al.
Factor H, membrane cofactor protein, and factor I mutations in patients with hemolysis, elevated liver enzymes, and low platelet count syndrome
Blood, December 1, 2008; 112(12): 4542 - 4545.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
S. Sacks and W. Zhou
New Boundaries for Complement in Renal Disease
J. Am. Soc. Nephrol., October 1, 2008; 19(10): 1865 - 1869.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
T. Kwon, M.-A. Dragon-Durey, M.-A. Macher, V. Baudouin, A. Maisin, M. Peuchmaur, V. Fremeaux-Bacchi, and C. Loirat
Successful pre-transplant management of a patient with anti-factor H autoantibodies-associated haemolytic uraemic syndrome
Nephrol. Dial. Transplant., June 1, 2008; 23(6): 2088 - 2090.
[Full Text] [PDF]


Home page
BloodHome page
A.-l. Stahl, F. Vaziri-Sani, S. Heinen, A.-C. Kristoffersson, K.-H. Gydell, R. Raafat, A. Gutierrez, O. Beringer, P. F. Zipfel, and D. Karpman
Factor H dysfunction in patients with atypical hemolytic uremic syndrome contributes to complement deposition on platelets and their activation
Blood, June 1, 2008; 111(11): 5307 - 5315.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A. M. Blom, F. Bergstrom, M. Edey, M. Diaz-Torres, D. Kavanagh, A. Lampe, J. A. Goodship, L. Strain, N. Moghal, M. McHugh, et al.
A Novel Non-Synonymous Polymorphism (p.Arg240His) in C4b-Binding Protein Is Associated with Atypical Hemolytic Uremic Syndrome and Leads to Impaired Alternative Pathway Cofactor Activity
J. Immunol., May 1, 2008; 180(9): 6385 - 6391.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
J. Caprioli and G. Remuzzi
A mouse model of non-Shiga toxin-associated haemolytic uraemic syndrome
Nephrol. Dial. Transplant., February 1, 2008; 23(2): 462 - 465.
[Full Text] [PDF]


Home page
BloodHome page
C. J. Fang, V. Fremeaux-Bacchi, M. K. Liszewski, G. Pianetti, M. Noris, T. H. J. Goodship, and J. P. Atkinson
Membrane cofactor protein mutations in atypical hemolytic uremic syndrome (aHUS), fatal Stx-HUS, C3 glomerulonephritis, and the HELLP syndrome
Blood, January 15, 2008; 111(2): 624 - 632.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
J. Caprioli and G. Remuzzi
Complement hyperactivation may cause atypical haemolytic uraemic syndrome gain-of-function mutations in factor B
Nephrol. Dial. Transplant., September 1, 2007; 22(9): 2452 - 2454.
[Full Text] [PDF]


Home page
Am. J. Pathol.Home page
M. M. Markiewski and J. D. Lambris
The Role of Complement in Inflammatory Diseases From Behind the Scenes into the Spotlight
Am. J. Pathol., September 1, 2007; 171(3): 715 - 727.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
A.-L. Sellier-Leclerc, V. Fremeaux-Bacchi, M.-A. Dragon-Durey, M.-A. Macher, P. Niaudet, G. Guest, B. Boudailliez, F. Bouissou, G. Deschenes, S. Gie, et al.
Differential Impact of Complement Mutations on Clinical Characteristics in Atypical Hemolytic Uremic Syndrome
J. Am. Soc. Nephrol., August 1, 2007; 18(8): 2392 - 2400.
[Abstract] [Full Text] [PDF]


Home page
haematolHome page
K. K. Swisher, J. T. Doan, S. K. Vesely, H. C. Kwaan, B. Kim, B. Lammle, J. A. Kremer Hovinga, and J. N. George
Pancreatitis preceding acute episodes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: report of five patients with a systematic review of published reports
Haematologica, July 1, 2007; 92(7): 936 - 943.
[Abstract] [Full Text] [PDF]


Home page
CJASNHome page
D. Kavanagh, A. Richards, V. Fremeaux-Bacchi, M. Noris, T. Goodship, G. Remuzzi, and J. P. Atkinson
Screening for Complement System Abnormalities in Patients with Atypical Hemolytic Uremic Syndrome
Clin. J. Am. Soc. Nephrol., May 1, 2007; 2(3): 591 - 596.
[Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
L. Bao, Y. Wang, A. Chang, A. W. Minto, J. Zhou, H. Kang, M. Haas, and R. J. Quigg
Unrestricted C3 Activation Occurs in Crry-Deficient Kidneys and Rapidly Leads to Chronic Renal Failure
J. Am. Soc. Nephrol., March 1, 2007; 18(3): 811 - 822.
[Abstract] [Full Text] [PDF]


Home page
J. Med. Genet.Home page
A. Servais, V. Fremeaux-Bacchi, M. Lequintrec, R. Salomon, J. Blouin, B. Knebelmann, J.-P. Grunfeld, P. Lesavre, L.-H. Noel, and F. Fakhouri
Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome
J. Med. Genet., March 1, 2007; 44(3): 193 - 199.
[Abstract] [Full Text] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020